The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.
about
Raltegravir for the treatment of HIV infection in adults and childrenRedefining the viral reservoirs that prevent HIV-1 eradicationDeep molecular characterization of HIV-1 dynamics under suppressive HAARTHIV drug resistance mutations in proviral DNA from a community treatment programR88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected CellsActivation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1).Current progress in the development of a prophylactic vaccine for HIV-1.HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patientsComplexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescentA therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infectionFeasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationAntiretroviral dynamics determines HIV evolution and predicts therapy outcome.Effects of political conflict-induced treatment interruptions on HIV drug resistanceModeling HIV persistence, the latent reservoir, and viral blips.HIV latency.HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.Pyroptosis, superinfection, and the maintenance of the latent reservoir in HIV-1 infection.Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Identification and characterization of HIV-1 latent viral reservoirs in peripheral blood.Mechanisms of HIV Transcriptional Regulation and Their Contribution to LatencyHigh prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.Mathematical Models of HIV Latency.
P2860
Q24186953-667BC3B9-6EFE-4A97-89A4-364DC23A5CC9Q26827255-02391ED0-05DE-436A-9175-C9A4B24F88B8Q28477677-05D715AF-2BB7-463C-A517-940F60827737Q28543156-F9A360B7-F0CE-4452-8C41-5CB2BC33AC9DQ33637221-8E0441FE-A2BC-4CA7-92A1-3961E1DCC275Q34005293-5E469920-BFDC-4FB2-A96B-2D2A1ACCA7DEQ34502108-176BF768-2C4F-47AF-A378-BA2CBFE7549CQ34508492-A013C7DA-F3BD-4434-BD32-8DDFDDF7F97BQ34606488-37B9ED49-C56D-416E-B507-9520D74A8928Q35115071-20A6CC4F-9138-469A-BEA4-95177FC4D803Q35878906-2F3229FC-FA72-4831-8142-3A73F724C1E8Q35953203-3F76EBCA-C5AE-4ED6-B62C-B8EC4A5ECF9AQ36066494-B39F045D-ED33-4C16-A5BB-4683C8A90EA6Q36098805-22071BF0-71C9-4ECE-9C01-49CAA621C781Q36330062-3EBCA463-95B7-4894-B992-BB346D4E8687Q36374300-79B98FDF-9908-414F-9B37-63A74575A2C3Q37175897-5553BE5E-7BD0-4DF6-A745-77582F2DB403Q37365718-9D209AE4-244F-4622-A34A-5DE459EB0182Q37974218-1DCCD7E4-7356-47E0-9640-AB0964C5AFD9Q38390465-524F4E35-A1BC-45D8-8B02-05FE2AB4671CQ38718273-C198A6AB-2D82-4971-91E6-7365D6D482D9Q39178197-FE9E7419-B166-41C5-86A6-6541D2EE227CQ40919787-DCCCB040-86AF-4EC6-BEC7-9D9B2D14E867Q41691236-A4917990-83C0-490F-8ADF-FDDE7E1EA507Q41769072-3CD187D9-17F1-4F51-AB33-6AEE6C2D4739Q41929325-214D11BE-93BB-4C0A-9892-92F1435B0E4BQ43036651-937F9288-951C-480C-90C5-01E3753B31B5Q47140686-A74C76A0-D479-4BA4-8E35-40D28759BE03Q47574091-C0CB10F1-8A27-416B-BE3F-93596D5C85CE
P2860
The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@ast
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@en
type
label
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@ast
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@en
prefLabel
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@ast
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@en
P2093
P2860
P356
P1476
The latent HIV-1 reservoir in ...... of pre-HAART drug resistance.
@en
P2093
Chris Verhofstede
P2860
P304
P356
10.1093/JAC/DKI038
P407
P577
2005-02-22T00:00:00Z